IL1B and colitis: The present study confirmed and extended this effect by detecting a substantial reduction of IL-1α, IL-1β, IL-6, TNF-α, INF-γ, G-CSF, IL-13, GM-CSF, IL-3, MIP-1α, RANTES, and eotaxin cytokines in response to UTA77 treatment in both colitis models.